Biosearch S A : publishes results for the third quarter of 2019

9M 2019

Disclaimer

This document is purely informative and does not constitute an offer of sale, exchange or acquisition, or an invitation to make purchase offers, on securities issued by any of the aforementioned companies. This financial information has been prepared in accordance with accounting regulations, however, since it is not audited information, it is not definitive information and could be modified in the future.

The hypotheses, information and forecasts contained herein do not constitute guarantees of future results and are exposed to risks and uncertainties; Actual results may differ significantly from those reflected in the assumptions and forecasts for various reasons. The information collected in this document may contain statements about future intentions, expectations or forecasts. All those manifestations, with the exception of those based on historical data, are manifestations of the future, including, among others, those related to our financial position, business strategy, management plans and objectives for future operations.

These intentions, expectations or forecasts are affected, as such, by risks and uncertainties that could determine that what actually happens does not correspond to them. These risks include, among others, seasonal fluctuations that may modify demand, sector competition, economic and legal conditions, restrictions on free trade and / or political instability in the different markets where Biosearch Life is present or in those countries where the company's products are manufactured or distributed.

Biosearch Life does not undertake to issue updates or revisions related to the forward-looking forecasts included in this Financial Information, in the expectations or in the facts, conditions or circumstances on which these forward-looking statements are based. In any case, the Company provides information on these and other factors that could affect the manifestations of the future, the business and the financial results of the Company, in the documents submitted to the National Commission of the Stock Market of Spain. All interested persons are invited to consult these documents.

2

3

Highlights

9M 2019

Decrease in sales and EBITDA in 9M 2019 mainly affected by probiotics

• Due mainly to a conjunctural adjustment in probiotics sales resulting from one of the main clients' overstock in 2018 that is being adjusted in 2019 and secondly to the decrease in sales of base products of the extracts business.
• Sustainable growth of lipids sales by 8.0%, mainly in the Senior and Children's segment.
• Significant decrease in EBITDA as a result of the decrease in sales of the products that contribute greater margin.
• Biosearch continues to diversify its product portfolio, it is working on a plan to reactivate sales and on a cost containment policy to reduce these exceptional impacts.

Visible product pipeline demonstrating Biosearch's commitment to R&D

Start of the new GERAS project

• To prevent and/or palliate the pathologies related to the loss of functionalities associated with age through the combination of extracts.
• Enhances the product differentiation from the extracts business.

GESTAHEALTH project

• Products designed to promote a healthier pregnancy and breastfeeding by modulating the microbiota in women.

Fully committed to sustainability

• Bio Certification as Ecological Producers and Traders in the Talayuela plant.
• Implementation of the identification of botanical species using molecular genetic techniques (DNA barcoding).